Changeflow GovPing Healthcare & Life Sciences INFEX Therapeutics Pyrrole Acid Synthesis Paten...
Routine Rule Added Final

INFEX Therapeutics Pyrrole Acid Synthesis Patent Grant

Favicon for changeflow.com USPTO Patent Grants - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO granted patent US12606524B2 to INFEX Therapeutics Limited for a novel method of synthesizing pyrrole acid derivatives that function as metallo-β-lactamase inhibitors. These compounds are designed for use in combination with carbapenem antibacterial agents to treat bacterial infections. The patent claims priority to application 18246777, filed October 6, 2021, and contains 3 claims under CPC classification C07D 207/48.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The USPTO issued patent US12606524B2 to INFEX Therapeutics Limited covering novel synthetic methods for pyrrole acid derivatives. The compounds are enzyme inhibitors specifically classified as metallo-β-lactamase inhibitors intended for combination therapy with carbapenem antibacterial agents. The patent was granted with 3 claims under the organic chemistry classification C07D 207/48.

Pharmaceutical companies developing carbapenem-based antibiotic regimens or researching β-lactamase inhibitor combinations should review this patent when assessing freedom-to-operate for related synthesis methods. Biotechnology firms in the anti-infectives space may find licensing opportunities with INFEX Therapeutics relevant to their product pipelines.

Archived snapshot

Apr 21, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Grants

Synthesis of pyrrole acid derivatives

Grant US12606524B2 Kind: B2 Apr 21, 2026

Assignee

INFEX Therapeutics Limited

Inventors

Andrew Wilkinson, Ian Cooper, David Orr, Jonathan Finlayson, Adam Bunt, James Kirkham, David Lyth, Kevin Blades

Abstract

This invention relates to the synthesis of compounds that can be used to treat bacterial infections in combination with other antibacterial agents, and more specifically in combination with a class of antibacterial agents known as carbapenems. The compounds resulting from the novel methods of the present invention are enzyme inhibitors and more particularly are metallo-β-lactamase inhibitors.

CPC Classifications

C07D 207/48

Filing Date

2021-10-06

Application No.

18246777

Claims

3

View original document →

Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 21st, 2026
Instrument
Rule
Branch
Executive
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
US12606524B2

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Patent IP Pharmaceutical compound synthesis Anti-infectives research
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!